Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment.

MLA

Miller, York E., et al. “Phase Ib Trial of Inhaled Iloprost for the Prevention of Lung Cancer with Predictive and Response Biomarker Assessment.” Frontiers in Oncology, vol. 13, Aug. 2023, p. 1204726. EBSCOhost, https://doi.org/10.3389/fonc.2023.1204726.

APA

Miller, Y. E., Ghosh, M., Merrick, D. T., Kubala, B., Szabo, E., Bengtson, L., Kocherginsky, M., Helenowski, I. B., Benante, K., Schering, T., Kim, J., Kim, H., Ha, D., Bergan, R. C., Khan, S. A., & Keith, R. L. (2023). Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment. Frontiers in Oncology, 13, 1204726. https://doi.org/10.3389/fonc.2023.1204726

Chicago

Miller, York E, Moumita Ghosh, Daniel T Merrick, Brandi Kubala, Eva Szabo, Lisa Bengtson, Masha Kocherginsky, et al. 2023. “Phase Ib Trial of Inhaled Iloprost for the Prevention of Lung Cancer with Predictive and Response Biomarker Assessment.” Frontiers in Oncology 13 (August): 1204726. doi:10.3389/fonc.2023.1204726.